Table 1 Patient characteristics in different AdvSM subtypes.
All | ASM/SM-AHN | SM-AML | MCL ± AHN | |
|---|---|---|---|---|
Number of patients, n (%) | 71 (100) | 30 (42) | 28 (39) | 13 (18) |
Age in years at Dx; median (range) | 58 (21–84) | 57 (27–67) | 59 (21–84) | 51 (27–74) |
Age in years at alloHCT; median (range) | 59 (21–84) | 59 (31–68) | 60 (22–84) | 55 (28–75) |
Male, n (%) | 49/71 (69) | 21/30 (70) | 19/28 (68) | 9/13 (68) |
Disease characteristics before alloHCT | ||||
Karnofsky performance score ≥90%, n (%) | 37/63 (59) | 18/27 (67) | 12/25 (48) | 7/11 (64) |
Serum tryptase ≥125 µg/L, n (%) | 18/44 (41) | 6/16 (38) | 6/16 (38) | 6/12 (50) |
Bone marrow mast cell infiltration ≥20%, n (%) | 27/40 (68) | 10/17 (59) | 7/15 (47) | 11/12 (92) |
KIT D816V positivity, n (%) | 52/62 (84) | 22/24 (92) | 23/25 (92) | 7/13 (54) |
SRSF2/ASXL1/RUNX1 positivity, n (%) | 25/48 (52) | 12/19 (63) | 11/19 (58) | 2/10 (20) |
Cytogenetics, aberrant, n (%) | 23/62 (37) | 5/23 (22) | 15/27 (56) | 3/12 (25) |
Cytogenetics, complex aberrant, n (%) | 9/62 (15) | 2/23 (9) | 4/27 (15) | 3/12 (25) |
Disease course before alloHCT | ||||
Lines of therapies; median (range) | 2 (0–5) | 1 (0–4) | 2 (0–5) | 3.5 (1–5) |
Involvement of tyrosine kinase inhibitors, n (%) | 35/71 (49) | 14/30 (47) | 9/28 (32) | 12/13 (92) |
Involvement of midostaurin/avapritinib, n (%) | 27/71 (38) | 10/30 (33) | 5/27 (19) | 11/13 (85) |
Years to alloHCT since AdvSM Dx; median (range) | 1.2 (0.1–16.7) | 1.5 (0.3.16.7) | 1.0 (0.0–12.7) | 1.2 (0.2–12.7) |
Years to alloHCT since AHN/AML Dx; median (range) | 1.1 (0.1–16.7) | 1.6 (0.2-16.7) | 0.3 (0.1–3.1) | 1.0 (0.2–12.7) |
